Correction to: A Subepithelial Lesion in the Colon Masquerading as Metastatic Prostate Cancer [0.03%]
Correction to：一项误诊为转移性前列腺癌的结肠亚黏膜病变病例报告
Rahil H Shah,Michael D Brophey,Megan Wachsmann et al.
Rahil H Shah et al.
[This corrects the article DOI: 10.14309/crj.0000000000001689.]. © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The America...
Published Erratum
ACG case reports journal. 2025 Jun 13;12(6):e01735. DOI:10.14309/crj.0000000000001735 2025
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial [0.03%]
初始转移性前列腺癌联合细胞减灭术、放疗或消融的IP2-ATLANTA内部预试验二期随机对照试验
Martin J Connor,Taimur T Shah,Johanna Sukumar et al.
Martin J Connor et al.
Background and objective: Cytoreduction of the primary prostate cancer, involved lymph nodes, and metastases may confer improved cancer control in de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC). ...
Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents [0.03%]
局灶性前列腺癌放疗的优化：探索与雄激素剥夺治疗及新型系统性药物的协同作用
Krishnan R Patel,Melissa Abel,Spyridon P Basourakos et al.
Krishnan R Patel et al.
Systemic therapy in the form of androgen deprivation therapy (ADT) is an important adjunct to radiation therapy which may serve to improve the curative potential of treatment; however, not all forms of systemic therapy which have demonstrated activity in metastatic prostate cancer will improve outcomes
Edward J Goetzl,Samuel L Washington
Edward J Goetzl
The incidence of metastatic prostate cancer (mPC) in the U.S. has increased in the past 20 years, five-year survival after diagnosis is only about 20% and treatment represents a major health care expense.
Artificial intelligence approaches for tumor phenotype stratification from single-cell transcriptomic data [0.03%]
单细胞转录组数据的肿瘤表型分层的人工智能方法
Namrata Bhattacharya,Anja Rockstroh,Sanket Suhas Deshpande et al.
Namrata Bhattacharya et al.
Using SCellBOW, we identified a hitherto unknown and pervasive AR-/NElow (androgen-receptor-negative, neuroendocrine-low) malignant subpopulation in metastatic prostate cancer with conspicuously high aggressiveness.
Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer [0.03%]
下调NONO可抑制转移性前列腺癌的增殖、迁移和侵袭
Anna-Lena Lemster,Sarah Grünhagen,Sarah Schmalfeld et al.
Anna-Lena Lemster et al.
Background: As prostate cancer (PCa) remains one of the leading causes of cancer-related death in men, it is important to develop effective therapeutic approaches for the treatment of metastatic PCa and to improve the acc...
The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy [0.03%]
放射配体治疗对SARS-CoV-2免疫原性影响的单臂队列研究：接受前列腺癌PSMA放射配体治疗的转移性前列腺癌患者的回顾性研究
Carsten S Kramer,Aleksandr Eismant,Aditi Mishra et al.
Carsten S Kramer et al.
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a rising threat for immunocompromised cancer patients. The reduced immune defense may be a result of the malignancy itself or a side effect of therapy. Whil...
Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors [0.03%]
雄激素受体信号传导抑制剂治疗的转移性前列腺癌患者中糖尿病与急性护理使用情况的关系
Michael A Liu,Rohit Raghunathan,Karie Runcie et al.
Michael A Liu et al.
This study aimed to assess the impact of diabetes on acute care use in older patients with metastatic prostate cancer on ARSIs....Methods: We used SEER-Medicare data for patients 66 years and older with de novo metastatic prostate cancer who were prescribed abiraterone, enzalutamide, or apalutamide from 2010 to 2017....Conclusion: Acute care use was common among patients with metastatic prostate cancer on ARSIs. Patients with diabetes experienced higher rates of acute care use compared with those without diabetes among all ARSI types.
Transperineal US-Guided Biopsy in Metastatic Prostate Cancer with Low Prostate Specific Antigen: A Case Report [0.03%]
低前列腺特异性抗原转移性前列腺癌的经会阴超声引导活检：一例报告
Seongeun Jung,Seong Sook Hong,Sung Hwan Bae et al.
Seongeun Jung et al.
Prostate specific antigen (PSA) is a crucial tool for detecting and monitoring of prostate cancer, and elevated levels of PSA often indicate disease progression. Higher PSA levels are generally associated with more aggressive cancers and an...
Trends in preventative bone health measures in prostate cancer: A cross-sectional study of patients at Calderdale and Huddersfield NHS foundation trust [0.03%]
英国卡尔德罗尔和哈德斯菲尔德NHS信托机构前列腺癌患者的骨健康预防措施的现状调查：横断面研究
Milly Finch,Richard Jacques
Milly Finch
Patients were split into three cohorts, cohort one- locally advanced prostate cancer treated with radiotherapy and 3 years of androgen deprivation therapy, cohort two- oligometastatic disease who receive first line radiotherapy and cohort three- metastatic prostate cancer encompassing hormone sensitive
耗时 0.15866 秒，为您在
48229835
条记录里面共找到 5196 篇文章 [XML]